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pidemiologyof liver abscess inThailandduring thepast decade
. Ratchatasettakul, P. Intaraprasong, S. Kiertiburanakul ∗
Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
Background: Liver abscess is still a common illness in clinical
ractice in Asia including Thailand. Amoebic liver abscess had been
eportedmore commonthanpyogenic inoriginduring thepast sev-
ral decades.Weaimed todetermine epidemiology amongpatients
ith liver abscess in the era of advance diagnosis and therapeutic
ntervention.
Methods: A retrospective cohort study was conducted in adult
atients who were admitted in Ramathibodi Hospital during 2000-
010.
Results: A total of 197 patients were included in the analysis
ithmedian age (IQR) of 52.7 (39.6-65.4) years old and 133 (67.5%)
ale. There were 131 (66.5%), 28 (14.2%), 6 (3.0%), 32 (16.4%)
atients were deﬁnite diagnosis of pyogenic, amoebic, mixed, and
ndeterminate of liver abscess, respectively. Most common organ-
sm recovered from blood culture was K. pneumoniae (17%). Of
hese, 134 (68.0%) patients had underlying condition; diabetic
ellitus were the majority (26.4%) followed by status post hep-
tobiliary procedure (21.8%). Patients with pyogenic liver abscess
ere older (53.6 vs. 38.8 years, p <0.001), had higher proportion
f underlying disease (77.9% s. 17.9%, p <0.001), higher propor-
ion of status post hepatobiliary procedure (27.5% vs. 0%, p =0.001).
or clinical presentations, patients with pyogenic liver abscess
ad lower proportion of abdominal or epigastrium pain (55.0%
s. 78.6%, p =0.021), hepatomegaly (89.3% vs. 64.9%, p =0.011),
nd systemic inﬂammatory response syndrome (75.0% vs. 46.6%,
= 0.006). For laboratory investigations, patients with pyogenic
iver abscess has higher band form (5 vs. 1.5%, p =0.031), lower
latelet (274,000 vs. 354,500/mm3, p=0.009), and higher blood
ugar (135 vs. 108mg/dL, p =0.018). There was no statistically sig-
iﬁcant different in radiologic ﬁndings. Median total of antibiotics
ay for treatment pyogenic liver abscess were longer than amoe-
ic liver abscess (61 vs. 37.5 days, p =0.031). Higher complications
ere found in pyogenic liver abscess than amoebic liver abscess
33.6% vs. 10.7%, p =0.021). Overall mortality rate was 8.6% and
here was no different in mortality between the 2 groups.
Conclusion: Pyogenic liver abscess was becoming a more com-
on than amoebic in origin. Knowing the difference between
atientswith amoebic and pyogenic liver abscessmay guide physi-
ian to make differential diagnosis and offer prompt treatment to
he patients.
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Background: SBT/ABPC 3g, QID is approved by regulatory
authorities and widely used for moderate to severe community-
acquired pneumonia (CAP) in the EU, USA, China, and South Korea
but not in Japan. However, there had been no evidence for efﬁcacy
and safety of SBT/ABPC 3g, QID from clinical trials for moderate
to severe CAP worldwide. We conducted the ﬁrst phase 3 trial of
SBT/ABPC 3g, QID in Japanese adults to evaluate efﬁcacy and safety
in moderate to severe CAP.
Methods: This was a multicentre, open label study. SBT/ABPC
3g, QID was administered intravenously for 3 to 14 days in 47
adults with moderate to severe CAP. Clinical and bacteriological
parameters were assessed at baseline, end of treatment (EOT), test
of cure (TOC) and long-term follow-up (LTFU). Causative organisms
were isolated from clinical specimens for susceptibility tests. Blood
samples were obtained from all the patients to conduct population
pharmacokinetic and pharmacodynamic analysis.
Results:A total of 47 subjectswere assigned to treatment in this
clinical study, and all of them received SBT/ABPC 3g, QID. Of these,
28 subjects (59.6%) had identiﬁed causative pathogens. The most
common single or multiple baseline causative pathogens identi-
ﬁedwereStreptococcuspneumoniae (n =14),Haemophilus inﬂuenzae
(n =9) and Moraxella catarrhalis (n =8). The clinical efﬁcacy rate at
TOC by major causative pathogens was 92.3% in subjects with S.
pneumoniae, 83.3% to 100% in subjects with H. inﬂuenzae, and 87.5%
in subjectswithM. catarrhalis. Thebacterial eradication rates at TOC
by major causative pathogens were 90.0% for S. pneumoniae, 75.0%
for H. inﬂuenzae, and 87.5% for M. catarrhalis. The clinical efﬁcacy
rate at TOC, primary endpoint, was 94.6%. In addition, percentage
of time aboveMIC of 50% or higher for all theMIC values reported in
this study (i.e. 0.06 to 16g/mL) was obtained for the QID regimen.
All adverse events were mild or moderate in severity.
Conclusion: SBT/ABPC 3g, QID demonstrated excellent clinical
and bacteriological effects on moderate to severe CAP. SBT/ABPC
3g, QID was well tolerated in the treatment of moderate to severe
CAP in Japanese.
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